论文部分内容阅读
目的观察非那雄胺联合特拉唑嗪治疗前列腺增生(BPH)的临床应用效果。方法随机选取2011年2月-2016年2月医院收治的BPH患者70例,根据随机数字法将70例患者分成观察组与对照组各35例。对照组应用特拉唑嗪治疗,观察组在特拉唑嗪治疗基础上联合非那雄胺治疗,对比2组前列腺症状(IPSS评分)、生活质量(QOL评分)、最大尿流率(MFR)及残余尿量等,对比2组用药后的不良反应情况。结果 2组患者治疗后IPSS、QOL及MFR等评分明显优于治疗前,且观察组IPSS、QOL及MFR等评分明显优于对照组,差异均有统计学意义(P<0.05)。2组治疗前后残余尿量对比均无明显差异(P>0.05)。治疗后观察组不良反应发生率为2.86%低于对照组的20.00%,2组对比差异显著(χ~2=5.0806,P<0.05)。结论 BPH患者应用非那雄胺联合特拉唑嗪治疗疗效理想,而且临床治疗安全可靠,值得推广应用。
Objective To observe the clinical effect of finasteride and terazosin in the treatment of benign prostatic hyperplasia (BPH). Methods Seventy patients with BPH were randomly selected in our hospital from February 2011 to February 2016. According to the random number method, 70 patients were divided into observation group and control group, 35 cases each. The control group was treated with terazosin, and the observation group was treated with finasteride on the basis of terazosin treatment. The IPSS score, quality of life (QOL), maximum flow rate (MFR) And residual urine volume, compared with adverse reactions after 2 groups of drugs. Results The scores of IPSS, QOL and MFR in the two groups were significantly better than those before treatment. The scores of IPSS, QOL and MFR in the observation group were significantly better than those in the control group. The differences were statistically significant (P <0.05). There was no significant difference in residual urine volume between the two groups before and after treatment (P> 0.05). The incidence of adverse reactions in the observation group after treatment was 2.86% lower than that in the control group (20.00%). There was significant difference between the two groups (χ ~ 2 = 5.0806, P <0.05). Conclusion The application of finasteride combined with terazosin in patients with BPH is effective, and the clinical treatment is safe and reliable, which is worth popularizing and applying.